March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
The Protective Effects Of Brimonidine For ARPE-19 And Müller Cells Exposed To Hydroquinone In Vitro
Author Affiliations & Notes
  • Mohamed Tarek
    Ophthalmology, Gavin Herbert Eye Institute, Irvine, California
  • Claudio A. Ramirez
    Ophthalmology, University of California, Irvine, Irvine, California
  • Marilyn Chwa
    Ophthalmology, University of California, Irvine, Irvine, California
  • G Astrid Limb
    Ocular Biology and Therapeutics, UCL Institute of Ophthalmology, London, United Kingdom
  • Baruch D. Kuppermann
    Gavin Herbert Eye Inst Dept Ophthal, University of California Irvine, Irvine, California
  • Cristina M. Kenney
    Ophthalmology, Univ of California-Irvine, Irvine, California
  • Footnotes
    Commercial Relationships  Mohamed Tarek, None; Claudio A. Ramirez, None; Marilyn Chwa, None; G Astrid Limb, None; Baruch D. Kuppermann, None; Cristina M. Kenney, None
  • Footnotes
    Support  Supported by Discovery Eye Foundation, Polly & Michael Smith Foundation, Beckman Initiative for Macular Research, Lincy Foundation, Iris & B. Gerald Cantor Foundation, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6419. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mohamed Tarek, Claudio A. Ramirez, Marilyn Chwa, G Astrid Limb, Baruch D. Kuppermann, Cristina M. Kenney; The Protective Effects Of Brimonidine For ARPE-19 And Müller Cells Exposed To Hydroquinone In Vitro. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6419.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study the protective effects of 0.1% brimonidine tartrate on ARPE-19 and Müller Cells (MIO-M1) exposed to hydroquinone (HQ), a toxic component found in cigarette smoke.

Methods: : ARPE-19 and MIO-M1 cells were initially pre-treated for 6 hours with one of four different concentrations (1/2x, 1x, 5x and 10x) of 0.1% brimonidine tartrate ophthalmic solution. The clinical dose (1x, 1mg/mL) is 0.1 ml of 0.1% brimonidine if injected into the 4ml human vitreous. After 6 hours of brimonidine pre-treatment, cells were exposed to 100 µM HQ dissolved in DMSO for 24 hours while brimonidine was still present. The production of reactive oxygen species and nitrogen species (ROS/RNS) were determined with 2`, 7`-dichlorodihydrofluorescein diacetate (H2DCFDA) dye assay. The lactate dehydrogenase (LDH) levels were measured using LDH cytotoxicity kit II.

Results: : ROS/RNS levels for ARPE-19 cells treated with 100µM HQ were 22420±610.6 compared to DMSO alone 5259±223. ARPE-19 cells pre-treated with 5x (19120±417.1,p=0.01) and 10x (5739 ±73.33, p<0.0001) doses of brimonidine showed significant lower levels of ROS/RNS. The 1/2x (21950±265.6,p>0.5) and 1x (21690±1031,p>0.5) brimonidine pre-treated cultures were similar to HQ alone. In MIO-M1 cells pre-treated with brimonidine the ROS/RNS levels were significantly lower at the 10x dose compared to 100µM HQ alone treated cells (15390±162.6 vs. 26950±542.7, p<0.0001). There are no significant changes in 1/2x , 1x and 5x doses.ARPE-19 cells pre-treated with 10x brimonidine showed significant lower LDH levels compared to 100µM HQ alone (1.6±0.1 vs. 2.633±0.1453,p=0.0042). There were no protective effects for the 1/2x (2.6 ±0.05774, p>0.8), 1x (2.5 ±0.05773, p>0.4) and 5x (2.527 ±0.06489, p>0.5) brimonidine doses. In the MIO-M1 cells, LDH levels did not decrease at any of the doses,: 2.516±0.06549,p>0.3; 2.554±0.04631,p>0.4; 2.494±0.07394,p>0.2 and 2.479±0.03371,p>0.1 for 1/2x, 1x, 5x and 10x doses respectively compared to 2.614±0.05744 for 100µM HQ alone treated cells.

Conclusions: : Brimonidine 0.1% has an in vitro protective effect against HQ induced toxicity, reducing the ROS/RNS levels at 5x and 10x doses in ARPE-19 cells and at 10x on MIO-M1 HQ treated cells. Pre-treatment with10x brimonidine also decreases the LDH levels in ARPE-19, but didn’t show any change in HQ treated MIO-M1 cells.

Keywords: drug toxicity/drug effects • retinal pigment epithelium • stress response 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×